AINGEAL, LLC

Biotech · Private

CN2097, a cyclic peptidomimetic compound that potentiates BDNF signaling pathways for rapid antidepressant effects

Grants
$911K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression$458,853
Federal grantDepartment of Health and Human Services · Phase I · Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression$452,622
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2095Sequor Pharamaceuticals LLC——
2096MIRNA ANALYTICS, LLC——
2097Marathoner Biosciences——
2098AINGEAL, LLC——
2099Manifold Capital Partners LP—$16M
2100Aspen Neuroscience——
2101Citryll——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.